FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter
FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.
FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.